Brian Bonomo, PA
Physician Assistant · Lecanto, FLNPI 1124012596
Payments from drug & device makers
Across 1,160 payments — averaging $481.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$176K
- UCB, Inc.$101K
- Regeneron Healthcare Solutions, Inc.$94K
- Janssen Scientific Affairs, LLC$55K
- Sanofi$40K
- E.r. Squibb & Sons, L.L.C.$30K
- plus $63K from 26 others
Across 5 payments — averaging $1046.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$5K
What the payments were for
- Consulting fees$6,7441%
- Speaking & faculty fees$447,38580%
- Travel & lodging$76,80314%
- Food & beverage$26,9545%
- Education$7960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 185 | $175,857 |
| UCB, Inc. | 196 | $100,863 |
| Regeneron Healthcare Solutions, Inc. | 187 | $93,614 |
| Janssen Scientific Affairs, LLC | 65 | $55,095 |
| Sanofi | 73 | $40,178 |
| E.r. Squibb & Sons, L.L.C. | 69 | $30,463 |
| Organon | 40 | $17,695 |
| AbbVie | 89 | $17,561 |
| Sun Pharmaceutical Industries Inc. | 41 | $13,317 |
| Lilly USA, LLC | 45 | $10,185 |
| Novartis | 51 | $918 |
| Amgen | 18 | $697 |
| Dermavant Sciences, Inc. | 32 | $545 |
| LEO Pharma Inc. | 19 | $434 |
| Kerecis Limited | 5 | $308 |
| Pfizer | 13 | $260 |
| Smith+Nephew | 7 | $139 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $84 |
| Organogenesis Inc. | 2 | $66 |
| Galderma Laboratories, L.p. | 3 | $48 |
| Arcutis Biotherapeutics, Inc. | 2 | $42 |
| Boehringer Ingelheim | 2 | $36 |
| Mayne Pharma Commercial LLC | 2 | $30 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $24 |
| Biofrontera Inc. | 1 | $22 |
| Fresenius Kabi USA, LLC | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| GSK | 1 | $18 |
| VYNE Pharmaceuticals Inc. | 1 | $17 |
| Incyte Corporation | 1 | $15 |
| Dermira, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tremfya$223,880
- DUPIXENT$141,230
- Bimzelx$89,866
- Sotyktu$27,555
- VTAMA$17,715
- Skyrizi$16,079
- ILUMYA$12,355
- OLUMIANT$9,186
- SIMPONI ARIA$4,544
- Cimzia$1,721
- Rinvoq$1,000
- Kerecis Omega3 Marigen$680
- Kerecis Omega3 SurgiClose$227
- Kerecis Omega3 GraftGuide$227
- Otezla$125
- ODOMZO$120
- EBGLYSS$106
How this compares
$558,681 in reported general payments places this provider in the 95th percentile of 8,062 physician assistant providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TremfyaGuselkumab | 42 | $563,491 |
| Humira(Cf) PenAdalimumab | 52 | $558,688 |
| Skyrizi PenRisankizumab-Rzaa | 23 | $467,703 |
| Dupixent PenDupilumab | 87 | $328,268 |
| Dupixent SyringeDupilumab | 60 | $291,689 |
| Cosentyx Unoready PenSecukinumab | 21 | $156,120 |
| Bimzelx AutoinjectorBimekizumab-Bkzx | 11 | $155,619 |
| OtezlaApremilast | 23 | $119,164 |
| SotyktuDeucravacitinib | 11 | $116,595 |
| OpzeluraRuxolitinib Phosphate | 18 | $35,153 |
| Clobetasol Propionate | 423 | $18,173 |
| Doxycycline Hyclate | 430 | $7,975 |
| Triamcinolone Acetonide | 677 | $6,360 |
| Metronidazole | 68 | $3,623 |
| Ivermectin | 11 | $3,197 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $175,857 | $563,49142 claims |
| AmgenOtezla | $697 | $119,16423 claims |
| E.r. Squibb & Sons, L.L.C.Sotyktu | $30,463 | $116,59511 claims |
| Incyte CorporationOpzelura | $15 | $35,15318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,062 physician assistant providers in Florida.
Other physician assistant in Lecanto
- Richard MarshallPort Orange$988K
- Audrey BeckerSt Augustine$689K
- Kevin WilliamsTampa$647K
- Melissa SingletonOcala$482K
- Reeli ReinuMaitland$427K
- Jeanelle KingMiami$424K
- Risha BellomoOrlando$397K
- Jason BergerClearwater$344K
- Ashley MillerGainesville$328K
- Nicole HillOrlando$319K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.